Xbrane Biopharma: XB003 deal with Alvotech - Redeye
Redeye provides its initial take on Xbrane following the sale of its Cimzia biosimilar (XB003) and part of its organization to Alvotech. The transaction significantly improves the balance sheet reducing the risk in the case.
ANNONS
Redeye provides its initial take on Xbrane following the sale of its Cimzia biosimilar (XB003) and part of its organization to Alvotech. The transaction significantly improves the balance sheet reducing the risk in the case.